From Concept to Cure: Breakthrough Therapeutics for High-Risk Neuroblastoma
Pioneering rationally engineered, targeted therapies for pediatric cancers driven by cancer stem cells.
Mission:
To save the lives of children diagnosed with rare but aggressive cancers, including high-risk neuroblastoma, through the development of novel, biomarker-driven therapeutics.
Vision:
To transform cancer care by translating cutting-edge research into safe, effective, and accessible therapies for children with limited treatment options.
Focus Area:
We target nucleolin (NCL), a protein overexpressed in many cancers, to eliminate both cancer cells and cancer stem cells (CSCs).
Our services
-
Cancer Agent Target Discovery
-
Preclinical In Vitro Studies
-
In Vivo Efficacy Testing
-
PK/PD and Toxicity Studies
Meet our team
-
Jason Huang, MD, CEO
Dr. Huang is a board certified neurosurgeon and served as President of Texas Association of Neurological Surgeons (2020-2021). He earned his medical degree from the Johns Hopkins University School of Medicine and completed his neurosurgery residency at the Hospital of the University of Pennsylvania. He is the author or co-author of over 200 peer-reviewed articles (including numerous high impact papers, with h-index of 44), numerous editorial reviews, and more than 20 book chapters. Additionally, he holds nine U.S. patents.
-
Erxi Wu, PhD, CTO
Dr. Wu has served as Chairman of the Advisory Board of Howfond Biopharma (Boston, 2006–2013), and was Deputy General Manager of Wuxi Howfond Pharmaceuticals and Director of the Boytler Institute for Cancer Drug Research (2013–2015). He is a member of the Advisory Board of the International Association of Biological and Medical Research (IABMR, since 2005) and a board member of the Chinese-American BioMedical Association (CABA, since 2005), among other professional affiliations. He has also served as a faculty senator at North Dakota State University.
Dr. Wu has published over 200 peer-reviewed scientific papers including many high impact ones (Nature Medicine, Nature Communications, JACS, etc.). He is a peer reviewer for more than 50 international journals including Cancer Research, Current Molecular Medicine, Antioxidants & Redox Signaling, Biomaterials, and Acta Pharmacologica Sinica, and serves on the editorial boards of six journals. He is frequently invited to give keynote speeches at national and international scientific conferences.
-
Dan Qi, PhD, Director, Product Development
Dr. Dan Qi received her Ph.D. in Biological Sciences and Molecular Genetics from Osaka University in 2015. At Neurofront Technology, she has played a key role in multiple cutting-edge projects focused on cancer stem cell biology, the discovery of liquid biomarkers for early disease detection, and prognostic tools for various malignancies.
More recently, Dr. Qi has been involved in therapeutic aptamer development, contributing to the screening and identification of DNA aptamers with diagnostic and therapeutic potential (Bioactive Materials, 2022; Genes & Diseases, 2023; Advanced Healthcare Materials, 2023). She has published 37 peer-reviewed articles and serves as a reviewer for more than 20 scientific journals.
-
Damir Nizamutdinov, MD, Director, Clinical Trials
Dr. Nizamutdinov leads the strategic design and execution of multi-site clinical trials, with a strong emphasis on methodological rigor, regulatory compliance, and data reproducibility. His work is primarily focused on neurodegenerative diseases and neuro-oncological conditions. He develops and oversees study protocols in alignment with FDA and IRB standards and manages cross-institutional collaborations to ensure consistent trial conduct.
In his role, Dr. Nizamutdinov provides clinical leadership and mentorship to research teams, ensuring strict adherence to trial protocols, prioritization of patient safety, and preservation of data integrity. He works closely with investigators, hospitals, and community partners to enhance participant recruitment and ensure the clinical relevance of each study. Additionally, he manages budgets, contracts, and operational resources to support long-term sustainability.